Amyotrophic lateral sclerosis – The tools of the trait
Identifieur interne : 002E55 ( Main/Corpus ); précédent : 002E54; suivant : 002E56Amyotrophic lateral sclerosis – The tools of the trait
Auteurs : Carsten W. Lederer ; Niovi SantamaSource :
- Biotechnology Journal [ 1860-6768 ] ; 2007-05.
English descriptors
Abstract
The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS‐specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate‐filament disorganization or axonal‐transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem‐cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.
Url:
DOI: 10.1002/biot.200600247
Links to Exploration step
ISTEX:2F15259809724AF8FC51AE652AD1E80CCEFA92F7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amyotrophic lateral sclerosis – The tools of the trait</title><author><name sortKey="Lederer, Carsten W" sort="Lederer, Carsten W" uniqKey="Lederer C" first="Carsten W." last="Lederer">Carsten W. Lederer</name><affiliation><mods:affiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</mods:affiliation></affiliation></author><author><name sortKey="Santama, Niovi" sort="Santama, Niovi" uniqKey="Santama N" first="Niovi" last="Santama">Niovi Santama</name><affiliation><mods:affiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2F15259809724AF8FC51AE652AD1E80CCEFA92F7</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/biot.200600247</idno><idno type="url">https://api.istex.fr/document/2F15259809724AF8FC51AE652AD1E80CCEFA92F7/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002E55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Amyotrophic lateral sclerosis – The tools of the trait</title><author><name sortKey="Lederer, Carsten W" sort="Lederer, Carsten W" uniqKey="Lederer C" first="Carsten W." last="Lederer">Carsten W. Lederer</name><affiliation><mods:affiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</mods:affiliation></affiliation></author><author><name sortKey="Santama, Niovi" sort="Santama, Niovi" uniqKey="Santama N" first="Niovi" last="Santama">Niovi Santama</name><affiliation><mods:affiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Biotechnology Journal</title><title level="j" type="sub">Healthcare Nutrition Technology</title><title level="j" type="abbrev">Biotechnology Journal</title><idno type="ISSN">1860-6768</idno><idno type="eISSN">1860-7314</idno><imprint><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2007-05">2007-05</date><biblScope unit="volume">2</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="608">608</biblScope><biblScope unit="page" to="621">621</biblScope></imprint><idno type="ISSN">1860-6768</idno></series><idno type="istex">2F15259809724AF8FC51AE652AD1E80CCEFA92F7</idno><idno type="DOI">10.1002/biot.200600247</idno><idno type="ArticleID">BIOT200600247</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1860-6768</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amyotrophic lateral sclerosis</term><term>Motor neuron disease</term><term>Neurodegeneration</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS‐specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate‐filament disorganization or axonal‐transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem‐cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Carsten W. Lederer</name><affiliations><json:string>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</json:string></affiliations></json:item><json:item><name>Niovi Santama Professor</name><affiliations><json:string>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Amyotrophic lateral sclerosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Motor neuron disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Neurodegeneration</value></json:item></subject><articleId><json:string>BIOT200600247</json:string></articleId><language><json:string>eng</json:string></language><abstract>The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS‐specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate‐filament disorganization or axonal‐transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem‐cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.</abstract><qualityIndicators><score>8.744</score><pdfVersion>1.6</pdfVersion><pdfPageSize>595.275 x 790.867 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1358</abstractCharCount><pdfWordCount>10099</pdfWordCount><pdfCharCount>64829</pdfCharCount><pdfPageCount>14</pdfPageCount><abstractWordCount>187</abstractWordCount></qualityIndicators><title>Amyotrophic lateral sclerosis – The tools of the trait</title><genre><json:string>article</json:string></genre><host><volume>2</volume><publisherId><json:string>BIOT</json:string></publisherId><pages><total>14</total><last>621</last><first>608</first></pages><issn><json:string>1860-6768</json:string></issn><issue>5</issue><subject><json:item><value>Review</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1860-7314</json:string></eissn><title>Biotechnology Journal</title><doi><json:string>10.1002/(ISSN)1860-7314</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/biot.200600247</json:string></doi><id>2F15259809724AF8FC51AE652AD1E80CCEFA92F7</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2F15259809724AF8FC51AE652AD1E80CCEFA92F7/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2F15259809724AF8FC51AE652AD1E80CCEFA92F7/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2F15259809724AF8FC51AE652AD1E80CCEFA92F7/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Amyotrophic lateral sclerosis – The tools of the trait</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><notesStmt><note>Telethon Foundation, Cyprus</note><note>Research Promotion Foundation of Cyprus – grant YGEIA - No. 0603/03;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Amyotrophic lateral sclerosis – The tools of the trait</title><author><persName><forename type="first">Carsten W.</forename><surname>Lederer</surname></persName><affiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</affiliation></author><author><persName><forename type="first">Niovi</forename><surname>Santama</surname></persName><roleName type="degree">Professor</roleName><note type="correspondence"><p>Correspondence: Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, PO Box 20537, 1678 Nicosia, Cyprus, +357‐22‐350557</p></note><affiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</affiliation></author></analytic><monogr><title level="j">Biotechnology Journal</title><title level="j" type="sub">Healthcare Nutrition Technology</title><title level="j" type="abbrev">Biotechnology Journal</title><idno type="pISSN">1860-6768</idno><idno type="eISSN">1860-7314</idno><idno type="DOI">10.1002/(ISSN)1860-7314</idno><imprint><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2007-05"></date><biblScope unit="volume">2</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="608">608</biblScope><biblScope unit="page" to="621">621</biblScope></imprint></monogr><idno type="istex">2F15259809724AF8FC51AE652AD1E80CCEFA92F7</idno><idno type="DOI">10.1002/biot.200600247</idno><idno type="ArticleID">BIOT200600247</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS‐specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate‐filament disorganization or axonal‐transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem‐cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Amyotrophic lateral sclerosis</term></item><item><term>Motor neuron disease</term></item><item><term>Neurodegeneration</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-12-14">Received</change><change when="2007-01-18">Registration</change><change when="2007-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2F15259809724AF8FC51AE652AD1E80CCEFA92F7/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>WILEY‐VCH Verlag</publisherName><publisherLoc>Weinheim</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1860-7314</doi><issn type="print">1860-6768</issn><issn type="electronic">1860-7314</issn><idGroup><id type="product" value="BIOT"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="BIOTECHNOLOGY JOURNAL">Biotechnology Journal</title><title type="subtitle">Healthcare Nutrition Technology</title><title type="short">Biotechnology Journal</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/biot.v2:5</doi><titleGroup><title type="specialIssueTitle">Brain‐specific Diseases</title></titleGroup><numberingGroup><numbering type="journalVolume" number="2">2</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2007-05">May 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="16" status="forIssue"><doi origin="wiley" registered="yes">10.1002/biot.200600247</doi><idGroup><id type="unit" value="BIOT200600247"></id></idGroup><countGroup><count type="pageTotal" number="14"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="publisher">Copyright © 2007 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</copyright><eventGroup><event type="manuscriptReceived" date="2006-12-14"></event><event type="manuscriptRevised" date="2007-01-12"></event><event type="manuscriptAccepted" date="2007-01-18"></event><event type="firstOnline" date="2007-03-07"></event><event type="publishedOnlineFinalForm" date="2007-05-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.10 mode:FullText" date="2010-06-28"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-07"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-15"></event></eventGroup><numberingGroup><numbering type="pageFirst">608</numbering><numbering type="pageLast">621</numbering></numberingGroup><correspondenceTo>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, PO Box 20537, 1678 Nicosia, Cyprus, <b>Fax:</b> +357‐22‐350557</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:BIOT.BIOT200600247.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="146"></count></countGroup><titleGroup><title type="main" xml:lang="en">Amyotrophic lateral sclerosis – The tools of the trait</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#a1"><personName><givenNames>Carsten W.</givenNames><familyName>Lederer</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Niovi</givenNames><familyName>Santama</familyName><degrees>Professor</degrees></personName><contactDetails><email>santama@ucy.ac.cy</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="CY" type="organization"><unparsedAffiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Amyotrophic lateral sclerosis</keyword><keyword xml:id="kwd2">Motor neuron disease</keyword><keyword xml:id="kwd3">Neurodegeneration</keyword></keywordGroup><fundingInfo><fundingAgency>Telethon Foundation, Cyprus</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Research Promotion Foundation of Cyprus – grant YGEIA</fundingAgency><fundingNumber>0603/03</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS‐specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate‐filament disorganization or axonal‐transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem‐cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Amyotrophic lateral sclerosis – The tools of the trait</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Amyotrophic lateral sclerosis – The tools of the trait</title></titleInfo><name type="personal"><namePart type="given">Carsten W.</namePart><namePart type="family">Lederer</namePart><affiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Niovi</namePart><namePart type="family">Santama</namePart><namePart type="termsOfAddress">Professor</namePart><affiliation>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</affiliation><description>Correspondence: Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, PO Box 20537, 1678 Nicosia, Cyprus, +357‐22‐350557</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>WILEY‐VCH Verlag</publisher><place><placeTerm type="text">Weinheim</placeTerm></place><dateIssued encoding="w3cdtf">2007-05</dateIssued><dateCaptured encoding="w3cdtf">2006-12-14</dateCaptured><dateValid encoding="w3cdtf">2007-01-18</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">146</extent></physicalDescription><abstract lang="en">The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS‐specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate‐filament disorganization or axonal‐transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem‐cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.</abstract><note type="funding">Telethon Foundation, Cyprus</note><note type="funding">Research Promotion Foundation of Cyprus – grant YGEIA - No. 0603/03; </note><subject lang="en"><genre>Keywords</genre><topic>Amyotrophic lateral sclerosis</topic><topic>Motor neuron disease</topic><topic>Neurodegeneration</topic></subject><relatedItem type="host"><titleInfo><title>Biotechnology Journal</title><subTitle>Healthcare Nutrition Technology</subTitle></titleInfo><titleInfo type="abbreviated"><title>Biotechnology Journal</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">1860-6768</identifier><identifier type="eISSN">1860-7314</identifier><identifier type="DOI">10.1002/(ISSN)1860-7314</identifier><identifier type="PublisherID">BIOT</identifier><part><date>2007</date><detail type="title"><title>Brain‐specific Diseases</title></detail><detail type="volume"><caption>vol.</caption><number>2</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>608</start><end>621</end><total>14</total></extent></part></relatedItem><identifier type="istex">2F15259809724AF8FC51AE652AD1E80CCEFA92F7</identifier><identifier type="DOI">10.1002/biot.200600247</identifier><identifier type="ArticleID">BIOT200600247</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>WILEY‐VCH Verlag</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002E55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:2F15259809724AF8FC51AE652AD1E80CCEFA92F7
|texte= Amyotrophic lateral sclerosis – The tools of the trait
}}
| This area was generated with Dilib version V0.6.23. |  |